Brief: Kaleido Biosciences Announces Completion Of Enrollment Of 350 Subjects In Controlled Study Of KB109 In Treatment Of Mild-To-Moderate COVID-19
04/01/2021 12:41
Jan 4 (Reuters) - Kaleido Biosciences Inc KLDO.O :
* KALEIDO BIOSCIENCES - ANNOUNCES COMPLETION OF ENROLLMENT
OF 350
SUBJECTS IN CONTROLLED STUDY OF KB109 IN TREATMENT OF
MILD-TO-MODERATE COVID-19
* KALEIDO BIOSCIENCES - CONTINUE TO EXPECT TOPLINE DATA FROM
SMALLER STUDY OF KB109 IN Q1 2021
Source text for Eikon: ID:nGNX98DCFX
Further company coverage: KLDO.O
((Reuters.Briefs@thomsonreuters.com;))